We are live on ! Find out more
NBSE

NeuBase Therapeutics, Inc. Common Stock
NBSE

Delisted

NBSE was delisted on the 10th of May, 2024.

Back to rankings

47 hedge funds and large institutions have $9.59M invested in NeuBase Therapeutics, Inc. Common Stock in 2015 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 14 increasing their positions, 15 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

7% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 15

29% less funds holding

Funds holding: 66 → 47 (-19)

37% less capital invested

Capital invested by funds: $15.3M → $9.59M (-$5.69M)

86% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 22

95% less call options, than puts

Call options by funds: $50K | Put options by funds: $1.06M

Holders
47
Holders Change
-19
Holders Change %
-28.79%
% of All Funds
1.31%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
14
Reduced
15
Closed
22
Calls
$50K
Puts
$1.06M
Net Calls
-$1.01M
Net Calls Change
-$651K

Top Buyers

Rank Fund Capital Flow
1
BIT
BlackRock Institutional Trust
California
+$1.08M
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$422K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$316K
4
Citadel Advisors
Citadel Advisors
Florida
+$117K
5
PNC Financial Services Group
PNC Financial Services Group
Pennsylvania
+$111K

Top Sellers

Rank Fund Capital Flow
1
BC
Broadfin Capital
New York
-$4.46M
2
TI
Turner Investments
Pennsylvania
-$1.34M
3
AllianceBernstein
AllianceBernstein
Tennessee
-$1.01M
4
Northern Trust
Northern Trust
Illinois
-$481K
5
Millennium Management
Millennium Management
New York
-$236K
Name Holding Trade Value Shares
Change 		Change in
Stake
Millennium Management
26
Millennium Management
New York
$66K -$236K -204 -77%
Balyasny Asset Management
27
Balyasny Asset Management
Illinois
$66K +$12.7K +11 +22%
EWM
28
Edge Wealth Management
New York
$66K +$63.7K +55 +1,100%
Deutsche Bank
29
Deutsche Bank
Germany
$60K -$12.7K -11 -17%
Morgan Stanley
30
Morgan Stanley
New York
$55K -$45.2K -39 -44%
WMC
31
Westwood Management Corporation
Illinois
$55K – – –
PPCM
32
Pillar Pacific Capital Management
California
$48K – – –
Bank of America
33
Bank of America
North Carolina
$45K +$39.4K +34 +486%
Simplex Trading
34
Simplex Trading
Illinois
$45K +$47.5K +41 New
T. Rowe Price Associates
35
T. Rowe Price Associates
Maryland
$32K – – –
State Street
36
State Street
Massachusetts
$29K -$2.32K -2 -7%
WSFS
37
Wilmington Savings Fund Society
Delaware
$28K – – –
CLOS
38
Compagnie Lombard Odier SCmA
Switzerland
$22K – – –
First Manhattan
39
First Manhattan
New York
$19K – – –
Creative Planning
40
Creative Planning
Kansas
$17K +$17.4K +15 New
Royal Bank of Canada
41
Royal Bank of Canada
Ontario, Canada
$14K -$4.63K -4 -24%
Bank of Montreal
42
Bank of Montreal
Ontario, Canada
$14K – – –
BIM
43
BlackRock Investment Management
Delaware
$12K – – –
AIM
44
Advantage Investment Management
Iowa
$6K – – –
Wells Fargo
45
Wells Fargo
California
$5K -$5.79K -5 -50%
Citigroup
46
Citigroup
New York
$4K – – –
AIG
47
American International Group
New York
$2K -$1.16K -1 -50%
BC
48
Broadfin Capital
New York
– -$4.46M -4,438 Closed
TI
49
Turner Investments
Pennsylvania
– -$1.34M -1,338 Closed
AllianceBernstein
50
AllianceBernstein
Tennessee
– -$1.01M -1,003 Closed
1
2
3

NBSE Hedge Fund Activity: Q3 2015 in Review

47 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q3 2015, worth a combined $9.59M — down 37% from $15.3M a quarter earlier.

Sellers outnumbered buyers: 22 funds closed out of NBSE and 3 opened new positions — a net loss of 19 holders — while 15 trimmed existing stakes and 14 added.

The largest buyer was BlackRock Institutional Trust, adding an estimated $1.08M. The largest seller was Broadfin Capital, exiting entirely with an estimated $4.46M sold.

  • 47 institutional investors held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q3 2015, down from 66 in Q2 2015.
  • Funds reported $9.59M of NeuBase Therapeutics, Inc. Common Stock stock for Q3 2015, down 37% quarter-over-quarter.
  • 3 funds opened new NeuBase Therapeutics, Inc. Common Stock positions in Q3 2015 and 22 closed out, a net change of -19 holders.
  • The largest NeuBase Therapeutics, Inc. Common Stock buyer in Q3 2015 was BlackRock Institutional Trust, an estimated $1.08M added.
  • The largest NeuBase Therapeutics, Inc. Common Stock seller in Q3 2015 was Broadfin Capital, an estimated $4.46M sold.

Based on aggregated 13F filings for Q3 2015.